Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension Study of ARGX-113-2009 with Efgartigimod PH20 SC in Bullous Pemphigoid
2021-003063-10Phase 3Active
- Sponsor
- argenx
- Start
- Dec 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa in Bullous Pemphigoid (BP), sponsored by argenx. Primary endpoint: Primary safety endpoint. Started Dec 2022; status: active.
02
Drugs
efgartigimod alfa
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on 2021-003063-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003063-10.